msdc-0160 and Alzheimer-Disease

msdc-0160 has been researched along with Alzheimer-Disease* in 1 studies

Trials

1 trial(s) available for msdc-0160 and Alzheimer-Disease

ArticleYear
An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease.
    Current Alzheimer research, 2014, Volume: 11, Issue:6

    Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.

    Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Central Nervous System Agents; Double-Blind Method; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Mental Status Schedule; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Thiazolidinediones; Treatment Outcome

2014